Company Overview of Oryzon Genomics S.A.
Oryzon Genomics S.A., a biopharmaceutical company, develops and commercializes biomarkers identified through genomics and proteomics in the fields of diagnostics, personalized medicine, and therapy. Its products pipeline comprises GynEC-DX, a diagnostic test for endometrial cancer; ColoBRAF, a genetic test that verifies the presence of the BRAF-V600E mutation in MSI-H tumors; and Cxbladder, a non-invasive bladder cancer diagnostic test. The company also develops small molecules and monoclonal antibodies for various indications, including leukemia and other cancers, PD/AD and other dementias, Huntington, viral infections, squamous cell cancer, prostate cancer, and endometrial cancer. In addit...
Sant Ferran 74
Cornellà de Llobregat
Founded in 2000
Key Executives for Oryzon Genomics S.A.
Co-Founder, Chairman, Chief Executive Officer, President and Member of Financial Advisory Board
Co-Founder, Scientific Director and Director
Global Chief Financial Officer, Executive Vice President, Director and Chairman of Audit Committee
Chief Intellectual Property Officer
Investor Relations Director
Compensation as of Fiscal Year 2015.
Oryzon Genomics S.A. Key Developments
Oryzon Genomics Appoints Board of Directors
Nov 4 15
Oryzon Genomics announced the appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as independent directors to the company's Board of Directors, effective November 3, 2015. The addition of three independent directors, approved by shareholders, strengthens the board of Oryzon, as the company prepares to go public on the Spanish Continuous Market in Madrid. Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell have substantial expertise and will be valuable contributors to Oryzon's mission and anticipated needs. Mr. Antonio Fornieles will act as Lead Director, Ms. Isabel Aguilera will act as Chairman of the Remuneration and Nomination Committee, and Mr. Ramon Adell will be chairing the Audit and Compliance Committee. Mr. Antonio Fornieles brings to Oryzon over 30 years of audit experience. Mr. Fornieles has been Second Vice Chairman at Abengoa SA since January 2015 and also serves as its lead director. Previously as Global Chief Operating Officer at KPMG. Ms. Isabel Aguilerais is currently a Non-Executive Director and adviser to various companies, such as Indra, Banco BMN, AEGON Spain and EGASA. Mr. Ramon Adell serves as Professor of Financial Economics and Accounting at the University of Barcelona.
Oryzon Genomics S.A. Presents at BIO-Europe 2015, Nov-04-2015 09:45 AM
Sep 21 15
Oryzon Genomics S.A. Presents at BIO-Europe 2015, Nov-04-2015 09:45 AM. Venue: Munich, Germany.
ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015
Sep 5 15
ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015 . Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 7, 2015